Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Silver ETF (AGQ) vs Boston Scientific Corporation (BSX) Price & Performance

ProShares Ultra Silver ETFTrade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Silver ETF vs Boston Scientific Corporation — how do they compare? ProShares Ultra Silver ETF trades at $80.6, while Boston Scientific Corporation trades at $51.69 (market cap $74.19B). Which is the better fit depends on your goals.

AGQBSX
Sector
Leveraged / InverseHealth
52-Week High
$400.47$108.14
52-Week Low
$49.73$42.63
Market Cap
$74.19B
Enterprise Value
$86.27B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Silver ETF

AGQ, the ProShares Ultra Silver ETF, trades at $81.00, down 1.07% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The leveraged ETF structure amplifies silver price moves, with recent volatility highlighted by a 9.39% surge on silver rallies but a 16% crash in June 2026. Financial ratios are not applicable as this is an ETF tracking silver futures.

Outlook hinges on silver price direction, offering amplified gains if silver rallies but severe decay in downturns. Key risks include structural decay from daily leverage resets and silver's sensitivity to Fed policy. Investors must weigh high volatility against silver's bullish momentum.

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Silver ETF

AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.

Read more on AGQ

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX